Chiesi Group today announced the results of the tanimilast Phase III PILASTER clinical study in Chronic obstructive pulmonary disease (COPD). The study did not meet its primary and secondary endpoints. There were no safety signals observed during the study.

The company would like to thank the internal teams, all the investigators and patients involved in the study for their partnership and commitment during the study. The quality of their work and excellence have been truly outstanding throughout this program.